drugset / Trial / NCT03768531
Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Phase 2
Withdrawn
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purposed of this research is to study the safety and clinical activity of the combination of nivolumab and cabiralizumab in people with resectable biliary tract cancers (BTC).
Timeline
- Start
- 2019-06-14
- Primary completion
- 2023-01
- Completion
- 2023-01
Outcome
Outcome not reported
Stopped (Enrollment): “No subjects were enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabiralizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |